Targeted therapies in advanced renal cell carcinoma: the role of metastatic sites as a prognostic factor

2014 ◽  
Vol 10 (8) ◽  
pp. 1361-1372 ◽  
Author(s):  
Paolo Grassi ◽  
Elena Verzoni ◽  
Luca Porcu ◽  
Isabella Testa ◽  
Roberto Iacovelli ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Prognostic Factor ◽  
Cell Carcinoma ◽  
Targeted Therapies ◽  
Renal Cell ◽  
Advanced Renal Cell Carcinoma ◽  
Metastatic Sites

Recent advances in the treatment of renal cell carcinoma and the role of targeted therapies

2008 ◽  
Vol 44 (15) ◽  
pp. 2152-2161 ◽  
Author(s):  
Simon Chowdhury ◽  
James M.G. Larkin ◽  
Martin E. Gore
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Targeted Therapies ◽  
Renal Cell ◽  
Recent Advances

scholarly journals Survival Among Advanced Renal Cell Carcinoma (ARCC) Patients with >2 Prior Targeted Therapies

2012 ◽  
Vol 23 ◽  
pp. ix272
Author(s):  
E. Calvo ◽  
R. Casciano ◽  
L. Stern ◽  
T. Brechenmacher ◽  
S. Stergiopoulos ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Targeted Therapies ◽  
Renal Cell ◽  
Advanced Renal Cell Carcinoma

scholarly journals Use of targeted therapies for advanced renal cell carcinoma in the Veterans Health Administration

2019 ◽  
Vol 8 (15) ◽  
pp. 6651-6661 ◽  
Author(s):  
Sherrie L. Aspinall ◽  
Xinhua Zhao ◽  
Mark C. Geraci ◽  
Chester B. Good ◽  
Francesca E. Cunningham ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Targeted Therapies ◽  
Renal Cell ◽  
Veterans Health Administration ◽  
Advanced Renal Cell Carcinoma ◽  
Veterans Health ◽  
Health Administration

Differential expressions of PD-1, PD-L1, and PD-L2 between the primary and metastatic sites in renal cell carcinoma.

2018 ◽  
Vol 36 (6_suppl) ◽  
pp. 616-616
Author(s):  
Xingming Zhang ◽  
Pengfei Shen ◽  
Hao Zeng
Keyword(s):  
Renal Cell Carcinoma ◽  
Prognostic Factor ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Cox Regression ◽  
Predictive Accuracy ◽  
Biological Information ◽  
Poor Prognostic Factor ◽  
Cox Regression Analysis ◽  
Metastatic Sites

616 Background: To evaluate the differential expressions of PD-1, PD-L1 and PD-L2 between the primary and metastatic sites of renal cell carcinoma (RCC), and to find potential factors influencing expression difference. Methods: We included cases of RCC histologically diagnosed at West China Hospital between January 2009 and November 2016. Clinicopathological data were retrospectively extracted. SPPS 22.0 and GraphPad Prism 6 statistical software were used for data analysis. Kaplan-Meier was used to analyze PFS and OS. R software was used to calculate predictive accuracy (PA). Results: A total of 163 patients were included in this study. Immunohistochemistry results suggested significant differential expressions of PD-1, PD-L1 and PD-L2 between the primary and metastasis, with a higher detection rate of the primary than metastasis. Meanwhile, the concordance rate of PD-L1 between the primary and metastasis was only 32.5% (27/83), with a significant statistically difference (χ2 = 4.664, p = 0.031) and poor consistency (Kappa = 0.229, p = 0.031). PD-1 and PD-L1 were highly expressed in the lung/lymph node and PD-L2 was highly expressed in visceral metastases. Survival analysis suggested that PD-1 positive either in the primary or metastasis was a poor prognostic factor for OS (HR: 1.59, 95% CI 1.08-2.36, P = 0.0195). The expression of PD-L1 in the primary was a poor prognostic factor for OS (HR 2.55, 95% CI 1.06-6.15, P = 0.0373). Although the predictive effect of PD-L1 expression on OS was not statistically significant in TKI treated patients, the OS time was shorter in PD-L1-positive patients than those negative (median OS 19.0 vs 41.0 months). In the whole cohort, the PA value of COX regression analysis was 0.683 for PFS, and the addition of PD-1 expression in the primary increased the PA value to 0.699. Conclusions: The assessment of immunological checkpoint-related protein in primary tumor may not be able to provide adequate information for clinicians to evaluate or predict the patient's treatment-related efficacy and prognosis. Biopsy or resection of the metastases may provide a more accurate biological information for clinician's decision-making and the patient's prognosis.

Data to decisions: The impact of online education on immunotherapy in advanced renal cell carcinoma.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e17076-e17076
Author(s):  
Kinjal Parikh ◽  
Katie Lucero ◽  
Charlotte Warren ◽  
Emily Sherene Van Laar ◽  
Ann Carothers ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Online Education ◽  
Cell Carcinoma ◽  
Targeted Therapies ◽  
Immune Checkpoint ◽  
Renal Cell ◽  
Advanced Renal Cell Carcinoma ◽  
Online Video ◽  
Educational Activities ◽  
The Impact

e17076 Background: Cytokine therapy was initially the only immunotherapy for patients with advanced renal cell carcinoma (RCC). The advent of targeted therapies ushered in a new area of precision medicine in the treatment paradigm. Recently, immunotherapy in the form of immune checkpoint inhibitors has shown improved outcomes as compared to targeted therapies and has become a mainstay in treatment. As immunotherapy use moves into earlier stages of disease and combination therapies are explored, education remains essential to optimize patient outcomes. Through the partnership between Medscape Oncology and the Society for Immunotherapy of Cancer, educational activities were designed to increase the knowledge and competence among oncologists surrounding the role of immunotherapy in patients with advanced RCC and uncover remaining educational needs. Methods: The 2 educational activities included a 30-minute online, video discussion with 2 faculty presenters and synchronized slides and a text-based online activity with 2 patient cases and interactive questions. Educational effectiveness was assessed with repeated paired pre/post assessment where learners served as their own controls. The first activity launched September 19, 2018, the second activity launched December 19, 2018, and the data were collected and are reported through December 27, 2019. Results: A total of 9474 learners participated from September 2018-December 2019 including 1029 oncologists. Participation in education resulted in significant improvements for oncologist who answered all pre/post questions for an activity during the study period (n = 302). Improvements in knowledge and competency were observed in the following areas: Knowledge regarding the latest clinical trial data on the use of cancer immunotherapies for the treatment of RCC (49% vs. 74%, p < .001). Knowledge regarding the immune checkpoint inhibitor regimens on the care of patients with RCC (49% vs. 70%, p < .001). Competence related to choosing the most appropriate regimen for patients with mRCC across the continuum of care (54% vs. 76%, p < .001). Conclusions: Participation in online, video- and case-based CME-certified educational activities resulted in statistically significant gains in oncologist knowledge and competency surrounding the use of immunotherapy in advanced RCC. These results demonstrate the value and benefit of multi-modal and sequential activities on improving knowledge and competence outcomes for oncologists caring for patients with advanced renal cell carcinoma.

Sign in / Sign up

Export Citation Format

Share Document